Innocrin announced that the Food and Drug Administration (FDA) has granted Fast Track designation to seviteronel (VT-464) for the treatment of patients with metastatic castrate-resistant prostate cancer (CRPC).
Some patients with resistance after treatment with abiraterone, enzalutamide or both, might respond to seviteronel therapy based on strong preclinical and clinical evidence. Treatment-resistance with these agents represents a major unmet medical need, especially with the widespread use and the high cross-resistance of cancers seen in patients exposed to them.
Seviteronel is an oral, once daily, selective CYP17 lyase inhibitor (target of abiraterone) and an androgen receptor (AR) blocker (target of enzalutamide).
For more information visit Innocrinpharma.com.